Qualms about gastrointestinal safety and lack of data in older age groups did not deter the FDA’s Allergenic Products Advisory Committee from giving its nod to recommend approval of Ragwitek, the sublingual ragweed allergy therapy for adults from Merck & Co. Inc. and Alk-Abello A/S. Read More
Shares of Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) climbed steadily on Tuesday after the company disclosed that it plans to sell 16.4 million shares of common stock at $6.50 apiece to entities managed by the Baupost Group LLC. The hedge fund increased its stake in Idenix from 27 percent to approximately 35 percent of outstanding shares. Read More
If Congress wants a healthy biopharma sector that continues to produce innovative therapies to cure the world’s ills, it needs to ensure that those therapies have strong patent protection. Read More
Although Tunitas Therapeutics Inc. has its namesake in California’s Tunitas Creek, which meanders from the Santa Cruz Mountains to the Pacific Ocean, the company’s progress has been anything but a long and winding road. Read More
Scientists from the Taiwanese Academia Sinica reported that they have developed an influenza vaccine that was broadly protective in mice and ferrets by focusing not on the amino acid sequence of the vaccine antigen, but on how many sugars were attached to those amino acids. Read More
Hapten Sciences Inc., of Memphis, Tenn., has partnered with Particle Sciences Inc., a drug delivery contract development and manufacturing organization, to progress its lead product, a vaccine developed to lessen or eliminate contact dermatitis from poison ivy, oak and sumac exposure, into the clinic. Read More
Cytodyn Inc., of Vancouver, Wash., said it plans to expand its clinical program for PRO 140 and inked a deal with Amarex Clinical Research LLC to prepare two Phase IIb trial protocols to explore additional therapeutic indications. Read More
Les Laboratoires Servier, of Paris, and Curie-Cancer, the body which leads the Institut Curie’s industry partner research activity, said they renewed their partnership with the aim of identifying therapeutic targets for treating triple-negative breast cancers. Read More
Alkermes plc, of Dublin, received a notice of allowance for U.S. Patent application 14/032,736, “Prodrugs of fumarates and their use in treating various diseases.” Read More
